文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

临床研究中的统计学争议:联合免疫治疗的早期自适应设计

Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies.
PubMed 文献 · Ann Oncol · 2017-01-01

文章讨论3+3设计在联合免疫治疗早期试验中缺乏灵活性,介绍了一种以低毒性和高免疫反应定义最优方案的自适应设计,并在黑色素瘤辅助肽疫苗联合新型佐剂的早期试验中实施。运行特征显示该方法能在合理样本量下以高比例有效推荐最优方案,作者认为该设计可广泛用于早期联合研究。

要点

  • 3+3设计在联合免疫治疗早期试验中缺乏灵活性,效率不足。
  • 自适应设计以低毒性和高免疫反应定义最优方案,并在黑色素瘤肽疫苗试验中实施。
  • 运行特征显示该方法在合理样本量下能以高比例有效推荐最优方案。

核心结论

  • 所提出的设计是一种实用的早期自适应方法,适用于联合免疫治疗方案。
  • 该设计可更广泛地应用于早期联合研究,并已在复发/难治性套细胞淋巴瘤的两种小分子抑制剂进行中的研究中应用。

研究设计与样本

  • 文章描述了一种用于识别最优方案的自适应设计的实施,最优方案定义为低毒性和高免疫反应。
  • 该设计在黑色素瘤辅助肽疫苗联合新型佐剂的早期试验中实施。

主要发现

  • 运行特征显示该方法能在合理样本量下以高比例有效推荐最优方案。
  • 该设计已在复发/难治性套细胞淋巴瘤的两种小分子抑制剂进行中的研究中应用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In recent years, investigators have asserted that the 3 + 3 design lacks flexibility, making its use in modern early-phase trial settings, such as combinations and/or biological agents, inefficient. More innovative approaches are required to address contemporary research questions, such as those posed in trials involving immunotherapies. DESIGN: We describe the implementation of an adaptive design for identifying an optimal treatment regimen, defined by low toxicity and high immune response, in an early-phase trial of a melanoma helper peptide vaccine plus novel adjuvant combinations. RESULTS: Operating characteristics demonstrate the ability of the method to effectively recommend optimal regimens in a high percentage of trials with reasonable sample sizes. CONCLUSIONS: The proposed design is a practical, early-phase, adaptive method for use with combined immunotherapy regimens. This design can be applied more broadly to early-phase combination studies, as it was used in an ongoing study of two small molecule inhibitors in relapsed/refractory mantle cell lymphoma.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Wages NA, Slingluff CL, Petroni GR, et al. Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies. Ann Oncol. 2017. PMID: 28011450. doi:10.1093/annonc/mdw681

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。